从放射治疗中取出STING:STING检查点介导辐射抵抗
The Journal of clinical investigation
|December 2, 2024
概括
两项新的研究揭示了YTHDF1和血氧酶1 (HO-1) 如何在放射治疗后抑制STING通路,从而阻碍抗瘤免疫力. 阻止这些抑制剂可以增强T细胞反应和瘤控制,这表明了新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 循环GMP-AMP合成/刺激干扰素基因 (cGAS/STING) 途径对于I型干扰素 (IFN-I) 和放射治疗 (RT) 后的抗瘤CD8+T细胞反应至关重要.
- 对cGAS/STING通路的调节失调可能会在RT后损害抗瘤免疫力.
研究的目的:
- 阐明抑制STING信号传递和在RT后废除抗瘤免疫力的机制.
- 确定潜在的治疗点,在RT期间增强抗瘤反应.
主要方法:
- 研究了IFN-I介导的YTHDF1诱导在树突细胞 (DCs) 在RT之后的作用.
- 研究了血氧酶1 (HO-1) 诱导和裂变对RT后cGAS/STING通路活性的影响.
- 评估了阻断YTHDF1和HO-1抑制功能对抗瘤免疫和瘤控制的影响.
主要成果:
- 在RT后的DC中,IFN-I诱导了YTHDF1,导致了cathepsin介导的STING降解.
- RT诱导HO-1,抑制了cGAS细胞质输出和STING的寡合化.
- 抑制YTHDF1和HO-1改善了抗瘤T细胞免疫力和RT后的瘤控制.
结论:
- 在RT之后,YTHDF1和HO-1是STING信号的关键抑制剂.
- 针对YTHDF1和HO-1提供了一个有希望的策略,通过增强抗瘤免疫力来提高放射治疗的疗效.
相关概念视频
Biological Effects of Radiation
15.3K
All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they...
15.3K
DNA Damage can Stall the Cell Cycle
9.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


